[Clinical experience with the use of piroxicam in fast-dissolving sublingual capsules in acute recurrent osteoarthritis]. 1993

G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
Divisione di Reumatologia, Ospedale S. Camillo di Roma.

Open, non comparative study to evaluate the efficacy and safety of piroxicam Fast Dissolving Dosage Form (FDDF) for sublingual administration in treatment of reacutized osteoarthritis. Fifty-four patients with flare-ups of osteoarthritis involving various joints were enrolled in the study. They were treated with 20 mg/die piroxicam sublingual tablets for a total of 4 weeks. Drug efficacy was evaluated on the basis of the variation of spontaneous pain, pain on passive motion, functional limitation and capacity of performing a specific activity. Intensity of spontaneous pain on the first day showed a statistically significant improvement (p < 0.0001) only 15 minutes after the drug administration. This improvement in pain intensity increased until day 3. All other efficacy parameters showed a statistically significant improvement (p < 0.0001) 7 days after the beginning of treatment. Local and systemic tolerability was good. No patient showed local side effects; only 6 patients experienced systemic side effects. In conclusion, piroxicam sublingual tablets for treatment of osteoarthritis flare-ups showed analgesic efficacy already 15 minutes after drug administration, and good anti-inflammatory efficacy with good local and systemic tolerability.

UI MeSH Term Description Entries
D008297 Male Males
D010003 Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. Arthritis, Degenerative,Osteoarthrosis,Osteoarthrosis Deformans,Arthroses,Arthrosis,Arthritides, Degenerative,Degenerative Arthritides,Degenerative Arthritis,Osteoarthritides,Osteoarthroses
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D010894 Piroxicam A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. CP-16171,Feldene,CP 16171,CP16171
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
March 1994, Minerva medica,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
December 1994, Minerva medica,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
January 1996, Clinical therapeutics,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
March 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
February 1985, Seminars in arthritis and rheumatism,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
June 2018, Pharmaceutical development and technology,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
June 2019, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
January 1998, British journal of urology,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
July 2011, Pharmaceutical research,
G Minisola, and C Bancheri, and A Bogliolo, and B Brundisini, and L Gospodinoff, and L Lucentini, and F Porzio, and G Perpignano
January 1993, Minerva ginecologica,
Copied contents to your clipboard!